According to a Yale News report, researchers within Yale University’s Faculty of Arts and Sciences are working at the intersection of fundamental and applied science, aiming to translate laboratory discoveries into therapies that can save lives. The work focuses on developing novel drugs for cancers and metabolic diseases.
At the center of this effort is Farren Isaacs, a professor of molecular, cellular and developmental biology. Isaacs leads a bioengineering lab that is part of the Systems Biology Institute on Yale’s West Campus. His research involves bioengineering genomes and reprogramming cells — a dual approach that both deepens scientific understanding of cellular mechanisms and enables the production of more effective protein- and peptide-based drugs.
“I believe that we do have a responsibility to help facilitate and steward innovations from academic labs towards real-world impact for broader benefit across society,” Isaacs told Yale News.
For university students, particularly those studying biology, biochemistry, or biomedical engineering, Isaacs’ work illustrates a growing career path: the translational scientist who moves discoveries from the bench to the bedside. It also highlights how major research universities like Yale are structuring programs — through institutes like the Systems Biology Institute — to support this kind of applied research within a liberal arts and sciences framework.
The Faculty of Arts and Sciences at Yale comprises more than 1,000 faculty members and over 40 departments and programs spanning the humanities, social sciences, and sciences. It provides instruction to students in Yale College and the Graduate School of Arts and Sciences, meaning undergraduates and graduate students alike can engage with faculty conducting this kind of translational research.
Isaacs’ lab is part of a broader trend in academic medicine and biotechnology: the push to shorten the timeline between a basic science discovery and a clinical treatment. By engineering cells to produce more effective therapeutic proteins and peptides, his team is working on strategies that could eventually lead to new classes of drugs for diseases that are currently difficult to treat.
The Yale News report did not specify which particular cancers or metabolic diseases the lab is targeting, nor did it provide a timeline for when any therapies might enter clinical trials. As with most early-stage academic research, the path from lab discovery to approved treatment is long and uncertain. However, the work represents a concrete example of how university-based scientists are increasingly taking on the role of innovators and entrepreneurs in the life sciences.